| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/25/2013 | CA2402718C Fish vaccine against piscirickettsia salmonis |
| 06/25/2013 | CA2347849C Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
| 06/25/2013 | CA2214453C Novel avian cytokines and genetic sequences encoding same |
| 06/20/2013 | WO2013090645A1 Methods for improving medical therapies |
| 06/20/2013 | WO2013090644A2 Anti-hiv antibodies having increased potency and breadth |
| 06/20/2013 | WO2013090636A1 Measurement of autoantibodies at low conductivity conditions with increased sensitivity |
| 06/20/2013 | WO2013090635A2 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | WO2013090633A2 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | WO2013090590A1 Use of n-hydroxysuccinimide to improve conjugate stability |
| 06/20/2013 | WO2013089877A2 Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs |
| 06/20/2013 | WO2013089496A1 Broad-spectrum neutralizing monoclonal antibody having high potential derived from h1n1-infected patients, and composition containing same for treating the virus |
| 06/20/2013 | WO2013089252A1 Modification of helper t cell-inducing polypeptide |
| 06/20/2013 | WO2013089166A1 Fimbriae type of porphyromonas gulae |
| 06/20/2013 | WO2013088304A1 Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| 06/20/2013 | WO2013088259A2 Methods of purifying antibodies |
| 06/20/2013 | WO2013088136A1 Ligand for dngr-1 receptor |
| 06/20/2013 | WO2013088109A1 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| 06/20/2013 | WO2013087993A1 Glycoprotein |
| 06/20/2013 | WO2013087992A1 Glycoprotein |
| 06/20/2013 | WO2013087874A1 Antibodies against the cytolethal distending toxin of c. difficile |
| 06/20/2013 | WO2013087857A2 Antibodies against c. difficile toxins |
| 06/20/2013 | WO2013087837A1 Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| 06/20/2013 | WO2013087789A1 Antibody isoform arrays and methods thereof |
| 06/20/2013 | WO2013087667A1 Attenuated and adapted strain of pseudomonas for delivering antigens |
| 06/20/2013 | WO2013087119A1 Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| 06/20/2013 | WO2013070615A8 Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| 06/20/2013 | WO2013063613A3 Methods and compositions related to intracellular neutralization by igg |
| 06/20/2013 | WO2013063412A3 Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions |
| 06/20/2013 | WO2013055874A3 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| 06/20/2013 | WO2013038385A3 Escherichia coli vaccine combination |
| 06/20/2013 | WO2013038375A3 Methods for making saccharide-protein glycoconjugates |
| 06/20/2013 | WO2013022808A3 Immunogenic protein conjugates and methods for making and using the same |
| 06/20/2013 | WO2012040562A3 Novel hiv-1 broadly neutralizing antibodies |
| 06/20/2013 | US20130157357 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 06/20/2013 | US20130157310 Method for Production and Use of Mite Group 1 Proteins |
| 06/20/2013 | US20130156859 Immunogenic composition |
| 06/20/2013 | US20130156813 Biomarkers for prostate cancer and methods for their detection |
| 06/20/2013 | US20130156811 Method of preventing early lawsonia intracellularis infections |
| 06/20/2013 | US20130156809 Recombinant Bacterium and Uses Thereof |
| 06/20/2013 | US20130156808 Vaccine comprising beta-herpesvirus |
| 06/20/2013 | US20130156807 Conjugates of synthetic tlr agonists and uses therefor |
| 06/20/2013 | US20130156804 Porin B (PorB) as a Therapeutic Target for Prevention and Treatment of Infection by Chlamydia |
| 06/20/2013 | US20130156803 Compositions and methods related to p6 |
| 06/20/2013 | US20130156802 Cholera Toxin Chimera and its Use as a Staph Vaccine |
| 06/20/2013 | US20130156801 Compositions and methods for exosome targeted expression |
| 06/20/2013 | US20130156800 Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof |
| 06/20/2013 | US20130156799 Contiguous overlapping peptides for treatment of birch pollen allergy |
| 06/20/2013 | US20130156798 Peptide composition |
| 06/20/2013 | US20130156797 Method for Preserving Alum Adjuvants and Alum-Adjuvanted Vaccines |
| 06/20/2013 | US20130156794 Immunotherapy using redirected allogeneic cells |
| 06/20/2013 | US20130156793 Insulin-resistance-improving drug |
| 06/20/2013 | US20130156792 Uniform field magnetization and targeting of therapeutic formulations |
| 06/20/2013 | US20130156791 Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| 06/20/2013 | US20130156787 Pharmaceutical composition for promoting angiogenesis, and method for screening for active substances for promoting angiogenesis |
| 06/20/2013 | US20130156784 Compositions Using Antibodies Directed To GPNMB And Uses Thereof |
| 06/20/2013 | US20130156783 Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| 06/20/2013 | US20130156781 Anti-dr4 agonist antibodies |
| 06/20/2013 | US20130156780 Annexin 1 Antibody |
| 06/20/2013 | US20130156778 Dendritic cell inhibitory proteins from ticks |
| 06/20/2013 | US20130156776 Compositions and methods for treating cancer and modulating stress granule formation |
| 06/20/2013 | US20130156775 Chlamydia trachomatis antigens |
| 06/20/2013 | US20130156768 Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| 06/20/2013 | US20130156766 Treatment of dry age related macular degeneration |
| 06/20/2013 | US20130156764 Neutralization of flt3 ligand as a leukemia therapy |
| 06/20/2013 | US20130156761 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same |
| 06/20/2013 | US20130156760 Protein Formulations and Methods of Making Same |
| 06/20/2013 | US20130156759 Methods of treating dementia using a gm-csf antagonist |
| 06/20/2013 | US20130156758 Optimized Fc Variants and Methods for Their Generation |
| 06/20/2013 | US20130156757 Targeting vegf-b regulation of fatty acid transporters to modulate human diseases |
| 06/20/2013 | US20130156756 Substituted Triazolopyridines |
| 06/20/2013 | US20130156755 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| 06/20/2013 | US20130156754 Optimized Fc Variants and Methods For Their Generation |
| 06/20/2013 | US20130156753 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| 06/20/2013 | US20130156751 Treatment of diseases |
| 06/20/2013 | US20130156728 Composition for neurological or autoimmune diseases |
| 06/20/2013 | US20130156702 Methods for the treatment and the diagnosis of cancer |
| 06/20/2013 | US20130156696 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 06/20/2013 | US20130156695 Use of zcytor17 ligand antagonists for treating inflammatory diseases |
| 06/20/2013 | US20130156691 Antibody Therapy |
| 06/20/2013 | DE112011102649T5 Medikament und Verfahren zur Prävention einer HIV-Kontamination, Prävention und Behandlung von Krankheiten, die durch HIV verursacht werden, und von mit HIV zusammenhängen-den Krankheiten, einschließlich AIDS Drug and method for the prevention of HIV contamination, prevention and treatment of diseases caused by HIV, and HIV-associated diseases including AIDS |
| 06/20/2013 | DE102011121238A1 Einzeldomänen-antikörper gegen clostridium difficile toxine Single-domain antibodies against Clostridium difficile toxins |
| 06/20/2013 | CA2863557A1 Process of expanding t cells |
| 06/20/2013 | CA2858276A1 Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| 06/20/2013 | CA2857321A1 Attenuated and adapted strain of pseudomonas for delivering antigens |
| 06/20/2013 | CA2855840A1 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | CA2855570A1 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | CA2853011A1 Methods of purifying antibodies |
| 06/19/2013 | EP2604695A1 Replication-defective arenavirus vectors |
| 06/19/2013 | EP2604692A1 Immunology treatment for biofilms |
| 06/19/2013 | EP2604682A1 Attenuated and adapted strain of pseudomonas for delivering antigens |
| 06/19/2013 | EP2604627A1 Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK |
| 06/19/2013 | EP2604626A1 Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof |
| 06/19/2013 | EP2604280A2 Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| 06/19/2013 | EP2604279A1 Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| 06/19/2013 | EP2604278A1 Anti-KIR antibodies, formulations, and uses thereof |
| 06/19/2013 | EP2604277A1 Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent |
| 06/19/2013 | EP2604276A1 Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment |
| 06/19/2013 | EP2604275A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/19/2013 | EP2603529A1 Anti-tenascin-c a2 antibodies and methods of use |
| 06/19/2013 | EP2603525A1 Antibodies to il-1beta and il-18, for treatment of disease |